ELAN

Elanco Animal Health Incorporated

Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested.

Elanco Animal Health Incorporated (ELAN) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
B
Factor Score 3.5 / 5.0
Revisions
C-
Factor Score 2.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 20.7
EV / EBITDA 15.9
Rev Growth YoY 11.3%
Gross Margin 56.2%
Price Return 3M 13.4%
Price Return 12M 21.4%
Catalyst Signal +0.28
Market Cap $13.4B
TTM Revenue $5.1B
Price / Sales 2.6
ROE -2.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B- (3.0) C- (2.1) B- (2.9) B (3.5) C- (2.0) C+ (2.7)
2026-11-09 B- (3.0) C- (2.1) B- (2.9) B (3.2) C- (2.0) C+ (2.6)
2026-11-08 B- (3.0) B- (2.9) B- (2.9) C+ (2.6) C- (2.1) C+ (2.7)
2026-11-07 B- (3.0) B- (2.9) B- (2.9) C+ (2.6) D+ (1.8) C+ (2.6)
2026-11-02 B- (3.0) B- (2.9) B- (2.9) C+ (2.6) F (0.4) C (2.3)
Page 1 of 10
…